Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients

Mara W. Rosenberg, Kevin Watanabe-Smith, Jeffrey W. Tyner, Cristina E. Tognon, Brian J. Druker, Uma Borate

Research output: Contribution to journalArticlepeer-review

Abstract

Acute myeloid leukemia (AML) is a heterogeneous malignancy with the most common genomic alterations in NPM1, DNMT3A, and FLT3. Midostaurin was the first FLT3 inhibitor FDA approved for AML and is standard of care for FLT3 mutant patients undergoing induction chemotherapy [1, 2]. As there is a spectrum of response, we hypothesized that biological factors beyond FLT3 could play a role in drug sensitivity and that select FLT3-ITD negative samples may also demonstrate sensitivity. Thus, we aimed to identify features that would predict response to midostaurin in FLT3 mutant and wild-type samples. We performed an ex vivo drug sensitivity screen on primary and relapsed AML samples with corresponding targeted sequencing and RNA sequencing. We observed a correlation between FLT3-ITD mutations and midostaurin sensitivity as expected and observed KRAS and TP53 mutations correlating with midostaurin resistance in FLT3-ITD negative samples. Further, we identified genes differentially expressed in sensitive vs. resistant samples independent of FLT3-ITD status. Within FLT3-ITD mutant samples, over-expression of RGL4, oncogene and regulator of the Ras-Raf-MEK-ERK cascade, distinguished resistant from sensitive samples. Overall, this study highlights the complexity underlying midostaurin response. And, our results suggest that therapies that target both FLT3 and MAPK/ERK signaling may help circumvent some cases of resistance.

Original languageEnglish (US)
Pages (from-to)2807-2818
Number of pages12
JournalOncotarget
Volume11
Issue number29
DOIs
StatePublished - Jul 21 2020

Keywords

  • Acute myeloid leukemia
  • Drug resistance
  • Drug sensitivity
  • FLT3
  • Midostaurin

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients'. Together they form a unique fingerprint.

Cite this